Good morning, ladies and gentlemen. Welcome to the Atea Pharmaceuticals 2026 Annual Meeting of Stockholders. At this time, all participants are in a listen-only mode. Following the formal remarks, we will reply to questions submitted by stockholders through the designated field on the web portal. I would now like to turn the conference call over to Jean-Pierre Sommadossi. Dr. Sommadossi, please proceed. Thank you, operator. Good morning and thank you for joining us today. My name is Jean-Pierre Sommadossi and I'm the founder, chairman, and CEO of Atea Pharmaceuticals. I'm very pleased to welcome you to our 2026 Annual Meeting of Stockholders. Before I call the meeting to order, I would like to take the opportunity to introduce all those in attendance at today's meeting. I begin by noting that all other members of the board, being Franklin Berger, our Lead Director, Jerome Adams, Howard Berman, Barbara Duncan, Arthur Kirsch, Bruno Lucidi, Polly Murphy, and Bruce Polsky, are present and participating in today's meeting. In addition to Atea board's member, joining me today is Andrea Corcoran, our Chief Financial Officer and EVP Legal, Janet Hammond, our Chief Development Officer, Arantxa Horga, our Chief Medical Officer, John Vavricka, our Chief Commercial Officer, Wayne Foster, our EVP and Chief Accounting Officer, and Jonae Barnes, our Senior VP, Investor Relations & Corporate Communications. I would also like to introduce Jennifer Plotnick and Mike Petry of KPMG, the company independent registered public accounting firm, who will be available to respond to questions from stockholders. Immediately after the official business of the meeting adjourn, we will provide a business overview and host a question and answer session. At this time, I call the meeting to order and will now turn the meeting over to Andrea, who will serve as secretary for today's meeting. Thank you, Jean-Pierre. On the virtual meeting webpage, you will find the rules of conduct for today's meeting. Please review these rules carefully. Just a reminder that only validated stockholders may ask questions in the designated field on the web portal. Also, out of consideration for others, please limit yourself to one question. All stockholders of record at the close of business on April 24th, 2026, or holders of a valid proxy are entitled to vote at today's meeting. Notice of the meeting was first sent or made available on April 27th, 2026 to all stockholders of record as of the close of business on the record date. As secretary, I will file the proof of mailing of notice of the meeting with the records of this meeting. The company has appointed Broadridge Financial Solutions to act as Inspector of Election. The Inspector of Election has signed the customary oath of office to execute his duties with strict impartiality. We will file this oath with the minutes of the meeting. The Inspector of Election has informed me that a quorum is present. We will now proceed to the formal business of the meeting. The time is now 9:03 A.M. Eastern Time, and the polls are now open for voting on all matters before the meeting. If you have not already voted and wish to vote, the polls will remain open until we finish presenting the proposal and close the polls. You do not need to vote during the meeting if you have already voted and do not wish to change your vote. There are three items of business to be considered by stockholders at today's meeting. The first item of business is a proposal to elect each of Dr. Jerome Adams, Dr. Howard Berman, and Barbara Duncan to serve as Class III directors for a three-year term ending in 2029. Our board recommends that stockholders vote for the election of each of these candidates. The second item of business is a proposal to ratify the Audit Committee's appointment of KPMG as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026. Our board recommends that stockholders vote for this item. The third item of business is the approval of the following resolution relating to the compensation of named executive officers. Resolved: That the company's stockholders approve, on an advisory, non-binding basis, the compensation of the named executive officers as disclosed in the company's proxy statement for the 2026 Annual Meeting of Stockholders pursuant to the compensation disclosure rules of the Securities and Exchange Commission, including the named executive officer compensation overview, the compensation tables, and narrative discussion. Our board recommends that stockholders vote for this item. If there are any questions regarding these items, please ask them now. Jonae, please present the first question. Thank you, Andrea. There are no questions regarding the items of business at this time. I will turn the call back over to you. Thank you. Please note that if you've sent in your signed proxy or if you have voted by telephone or internet, you do not need to vote now during the meeting. Any stockholder who has not yet voted or wishes to change their vote may do so by clicking on the voting button on the web portal and following the instructions there. We will close the polls in 90 seconds. The time is now 9:08 Eastern Time, and the polls are now closed for voting on the proposals before the meeting. According to the Inspector of Election, the preliminary voting report shows that the three candidates for election to the board have been duly elected. The appointment of KPMG as the company's independent registered public accounting firm for 2026 has been ratified. The resolution to approve, on an advisory non-binding basis, the compensation of the company's named executive officers has been approved. We will disclose the final tally of the votes in a current report on Form 8-K that we will file within four business days following this meeting. I'll now turn the meeting back to Jean-Pierre. Thank you, Andrea. Now I will present a brief business update, and then we would be available to answer any questions. Over the past year, we have made significant progress advancing our global phase III program, evaluating the regimen of bemnifosbuvir and ruzasvir with a potential best-in-class profile for the treatment of hepatitis C and broadening our antiviral pipeline with a potential first-in-class product candidate for the treatment of hepatitis E. Looking ahead, the second half of 2026 is expected to be a catalyst-rich year for Atea shareholders. Our upcoming key milestones include the delivery of results from our two phase III HCV trials. We are on track to announce top-line results from C-Beyond, our North American trial, mid-year, and top-line results from C-Forward, our ex-North American trial, around year-end. In addition, within the next few weeks, we expect to advance AT-587, our product candidate for HEV, into a first-in-human phase I program. These upcoming milestones are grounded in the strong execution we delivered over the past year. Late last year, we completed enrollment in C-Beyond with more than 880 patients, representatives of the genotypes and demographics seen in the U.S. and Canada. In C-Forward, we have enrolled now over 99% of patients and expect to complete enrollment next week. This trial includes a more diverse patient population, including less prevalent HCV genotype 4, 5, and 6, supporting the potential for a broad label. Over the last year, we presented and published several data sets supporting the potential best-in-class profile of our HCV regimen. Results from our phase II study showed a 98% Sustained Virologic Response 12 or cure in treatment-adherent patients and 95% Sustained Virologic Response 12 overall, with a favorable safety profile. This data reinforce our confidence in the phase III program and in the potential of our regimen, if approved, to expand access to treatment and cure more patients in the global HCV market. At our key opinion leader event held last year, leading hepatologists and prescribers in the U.S., Canada, and Europe emphasized the need for shorter, simpler and more accessible HCV treatment options. Our regimen was consistently recognized as differentiated based on its short treatment duration, low risk of drug-drug interaction, and convenience with no food effect. These attributes are especially relevant as the HCV patient population evolves today and the burden of untreated disease remains significant. There are up to 4 million people in the United States and approximately 50 million people worldwide infected with HCV. The HCV market is substantial, with approximately $1.3 billion in annual net sales in the U.S., which represent 50% of the $2.6 billion global market. Late last year, we expanded our antiviral hepatitis pipeline to address a major unmet need in immunocompromised patients with chronic Hepatitis E, a liver disease for which there is currently no approved therapy. In this at-risk population, the disease can progress rapidly to cirrhosis within three to five years if left untreated. We have completed clinical trial application, enabling studies for our product candidate AT-587 and expect to shortly begin a first-in-human study. Preclinical results presented earlier this year at CROI and EASL demonstrated high in vitro antiviral potency of AT-587 against HEV, supporting AT-587 as a potential first-in-class inhibitor for HEV infection. Importantly, with $256 million in cash and investment as of March 31st, 2026, we have the financial resources and are well-positioned to complete our phase III HCV program and advance our HEV development program. We expect our cash runway to extend through 2027. In closing, we remain focused on advancing program, developing best or first-in-class therapies for serious antiviral diseases, delivering in a timely manner key milestones, and creating long-term value for our shareholders. Thank you for your continued support and confidence in our team and mission. Thank you, Jean-Pierre. If any stockholder would like to ask a question regarding the business of the company, please submit your question through the web portal. Please note that we will only be answering questions that are within the parameters of the rules of conduct, and only stockholders who have logged into the meeting using their 16-digit control number are able to submit a question through the web portal. If we are unable to answer your question due to time constraints or other reasons, we will reply to your question by email after this webcast concludes if you wish to share your email address with us. We will now pause a moment to assemble the questions. Jonae, please present the first question. There are no questions at this time, and we've reached the conclusion of our Q&A period. Thank you, Jonae, and I want to thank you for attending and for your interest in Atea Pharmaceuticals. Thank you again for joining us and your continued support of Atea. The meeting is now concluded and you may disconnect at this time.